IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients. They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies. Episode Timestamps: 00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray. 00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints. 00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival. 00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead. 00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer. 00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies. 00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy. 00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation. The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment. They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology. Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth. This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode Timestamps 00:00 – Introduction and Vir’s transformation story 00:40 – Marianne De Backer’s 30+ year pharma journey 02:42 – Vir’s origins and post-COVID strategic pivot 04:42 – Taking over as CEO during a crisis 06:33 – Lessons from the biotech downturn (“biotech winter”) 08:56 – Astellas partnership and T-cell engager strategy 09:52 – ProXtend platform: masked T-cell engagers explained 13:24 – Clinical data, safety, and tumor targeting 15:32 – Integrating new teams and scientific expertise 17:38 – Expanding the pipeline (HER2, EGFR, oncology) 19:50 – Hepatitis delta program and commercialization plans 22:11 – Funding strategy and biotech market outlook 25:37 – FDA interactions and regulatory perspective 28:13 – AI in drug discovery and clinical trials (Daisy platform) 31:34 – Culture: grit, ingenuity, collaboration, authenticity 34:21 – Personal reflections and leadership mindset 35:46 – Closing thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Marianne De Backer; LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/ Website: https://www.vir.bio/ Follow IDEA Pharma On; Website: https://www.ideapharma.com/ LinkedIn: https://www.linkedin.com/company/idea-pharma Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making. Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma. SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation. Keep up with the guests; Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/ John Barry - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/ Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/ Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/ Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/ Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project.Episode Timestamps;00:00 Introduction and Welcome00:27 Rick's Background and Project Overview02:31 Client Team Introductions05:32 Collaboration and Challenges13:29 Defining the Mechanism and Market Positioning23:52 Communication and Alignment27:48 Navigating Internal and External Communication33:15 Launch, Reflections, and Lessons Learned41:14 Final Thoughts and Acknowledgements Keep up with the guests;Robyn Blackburn - Director Global Commercial Strategy CAR-T at Kite Pharmahttps://www.linkedin.com/in/robyn-blackburn-805b8b13/Jayne Butler - Director of Strategic Initiatives at Fingerpaint Brandinghttps://www.linkedin.com/in/jaynebutler/Tracey Sacco - Former SVP Global Strategic Marketing at Acceleronhttps://www.linkedin.com/in/tracey-sacco-53 2a034/Rick Ritacco - Head of Growth and Innovationhttps://www.linkedin.com/in/rritacco/ Follow Mike Rea On;Website: https://ideacollider.simplecast.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools. With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.Chapter Summaries;00:00 Introduction and Guest Welcome00:27 Susan Galbraith's Career Journey02:37 Defining Success in Oncology R&D05:01 Early Phase Drug Development07:09 Digital Health and Patient Experience12:37 Global Collaboration and Innovation15:05 AI and Future of Oncology28:08 Diversity and Inclusion in Clinical Trials33:46 Mentorship and Career Advice37:45 Challenges and Future Outlook in Oncology42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith;LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.

Quitting is a valuable skill. It’s important for dealing with uncertainty, yet we are quite bad at exercising it. It should not be just about sticking to things. Quitting is also good, particularly when we have to start most things. Persisting at something when it’s worthwhile is definitely a good character trait but persisting at something when it’s no longer worthwhile is not a good character trait. Calibrate around the notion, “is it worthwhile to stick? "

The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care. Companies such as Openwater, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke.In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company. Tune in for more insights! Key Highlights[01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory[03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook[05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners[07:32] Why the One Laptop Per Child (OLPC) initiative didn’t work[09:35] How she co-created the world’s first holographic video system from an idea that seemed impossible [12:07] Physicists’ predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologists’ culture of looking for any proof that they are right [17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy [18:24] How did Openwater start, and what does the company deal with? [20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims[26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation[31:42] The side effect of psychedelics in depression treatment [37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry [40:21] The operating and hiring principles of the Openwater company[49:00] How to link with Mary Lou Jepsen Don’t forget to Follow, Rate, Review, Like, and Share! Let’s Connect!Follow Mary Lou Jepsen on her;Personal website:https://www.maryloujepsen.com/Company website: https://www.openwater.cc/LinkedIn: https://www.linkedin.com/in/majepsen/Twitter: https://twitter.com/mljmljmljFacebook: https://web.facebook.com/maryloujepsen?_rdc=1&_rdr More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy. She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine.Additionally, she delves into the major functional areas of compounding pharmacy, the reasons behind the decline in compounding pharmacy over the years, her source of ideas, and how she judges success. Moreover, Sherine expounds on the organizational structure within the pharmacy, how far she plans into the future, and her journey in business consulting. Tune in! During this episode, you will learn about;[01:23] About Sherine Khalil[05:36] Sherine’s transition from the nonprofit world to academic medicine[11:25] Is her curiosity self-directional?[13:55] About compounding pharmacy and its major function areas[15:55] Reasons for the decline in compounding pharmacy over the years[19:00] Sherine’s source of ideas. What’s her process of assessing development[21:10] Organizational structure and hierarchy within the pharmacy[22:25] How she judges success. What will work or not work[23:54] How far Sherine plans into the future[28:06] What her Quarter 1 & 2 goals look like for her amidst covid in 2022[30:13] What’s in Sherine’s organizational structure that makes her more agile than other companies[32:19] Sherine’s biggest idea in telehealth[39:33] Sherine’s journey in business consultancy[44:29] Her source of motivation[46:36] Sherine’s book recommendations[48:04] One thing Sherine wishes she could have been asked[52:13] To connect with Sherine Let’s Connect!Follow Sherine Khalil on;LinkedIn: https://www.linkedin.com/in/sherinekhalilEmail: skhalil@vcprx.comFollow Valor Compounding Pharmacy;Website: https://valorcompounding.com/More ProductsFollow Mike Rea on;● Website: https://www.ideapharma.com/● Twitter: https://twitter.com/ideapharma● LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality. Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha, what innovation management entails, and how data works and impacts company decisions. Additionally, he expounds on the right KPIs for pharmaceuticals, platforms & tools for better data organization, creating value for your company as well as the future of data.Tune in for more!During this episode, you will learn about;[00:27] Introducing the episode[00:40] Know our guest “Matthew Wahlrab”[04:47] His career path from intellectual property to where he is now[12:00] How data works[16:55] Defining innovation management[21:16] How data impacts company decisions[22:15] About Matthew's company Rapid Alpha & what they do[24:48] Matthew’s special sources [26:29] Matthew’s approach to Green flags & who should be working where[29:49] Getting your timing right[32:22] The right KPIs for pharmaceuticals[37:49] Platforms & tools for better data organization[43:04] Creating value in an enterprise[47:52] The future of data[51:44] Book recommendations from Matthew[55:45] Best way to connect with Matthew Wahlrab[56:31] One question he wishes to have been askedLet’s Connect!Follow Matthew Wahlrab on;LinkedIn: https://www.linkedin.com/in/matthew-wahlrab/Follow Rapid Alpha on;Website: https://rapidalpha.com/LinkedIn: https://www.linkedin.com/company/rapidalpha/ More ProductsFollow Mike Rea on;● Website: https://www.ideapharma.com/● Twitter: https://twitter.com/ideapharma● LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today’s episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization.Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture. Tune in! During this episode, you will learn about;[00:22] Episode introduction[00:36] Today’s focus; Asymmetric learning and its impact on culture[00:55] Know our guest; John Waid[03:01] What is culture?[05:41] The purpose of an organization[10:36] Examples of companies and their values[14:46] Why he came up with the principle of three values[16:34] The importance of respectful spirit value[19:19] Why you should know your; purpose, mission, values, and principles of behavior[22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions[26:27] Chick-fil-A’s values and culture[32:31] Why one company outperforms the other[37:16] Can culture be built virtually? [40:25] How to start building a successful workplace culture [42:53] Disruption vs Innovation[45:09] How to connect with John Waid Love the show? Follow, Rate, Review, Like, and Share! Let’s Connect!Follow John Waid on;Website: https://www.corporatecultureconsulting.com/LinkedIn: https://www.linkedin.com/in/johnwaid/Facebook: https://www.facebook.com/c3culture/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/